Breast Cancer

A retrospective study used machine learning to predict treatment response and survival rates in breast cancer patients from an underserved, inner-city population. The study examined the impact of tumor subtypes and socioeconomic factors on outcomes. Machine learning models reveal no association between pathological complete response and patient demographics but highlight the significance of tumor subtypes...

New research shines a light on fighting a difficult type of breast cancer, known as triple-negative breast cancer, by focusing on an enzyme that protects these cancer cells. This discovery opens up possibilities for treatments that are not only effective but that may also be gentler on the body. Research identifies the enzyme NUDT5 as...

A preliminary study reveals that tiny particles released by cancer cells may predict the effectiveness of breast cancer treatment, particularly for those facing triple-negative breast cancer. This research offers a promising approach to personalizing treatment plans, potentially improving outcomes for patients and providing new hope to individuals and their families navigating this challenging diagnosis. Dealing...

A type of signalling molecule called filamin A may play a key role in the battle against triple-negative breast cancer. This research could lead to more personalized and effective treatments by targeting the unique ways filamin A influences cancer growth and spread, offering new hope for those affected by this type of cancer, which is...

Tucatinib combined with trastuzumab and capecitabine improved brain metastasis survival in a recent clinical trial. The combination was found to be safe and may delay the development of new brain lesions in patients with breast cancer. Treatments targeting human epidermal growth factor receptor 2  (ERBB2) significantly improve outcomes in patients with ERBB2-positive breast tumors. Despite...

In the front-line treatment of human epidermal growth factor receptor 2-positive patients, dalpiciclib with pyrotinib demonstrates promising efficacy and acceptable tolerability. A highly selective, small-molecule CDK4/6 inhibitor, palbociclib (SHR6390), was recently authorized in China for hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative advanced breast cancer (ABC).  Pyrotinib is an orally administered, irreversible pan-ErbB...

Atezolizumab therapy for advanced or metastatic triple-negative breast cancer (TNBC) was found to have a similar safety profile to those of previous trials and was associated with changes to the immune system in a recent retrospective study.  Triple-negative breast cancer (TNBC) refers to breast tumors that lack hormone receptors (HR) and human epidermal growth factor...

A recent survey study concluded that to encourage metastatic breast cancer patients to exercise, individualized, accessible programs with clear instructional materials should be created. To improve patient engagement and program evaluation, there is a need for country-specific strategies, reimbursement clarification, and interdisciplinary collaboration. Despite notable progress in the early detection and therapeutic interventions for breast...

Trastuzumab deruxtecan significantly improved overall survival compared to trastuzumab emtansine in a multi-center phase 3 trial. Human epidermal growth factor receptor 2 (HEGFR 2) is overexpressed in 15–20% of breast cancers. Currentlu, for HER2-positive metastatic breast cancer, pertuzumab and trastuzumab, plus a taxane, are first-line treatments. Second-line therapy is trastuzumab deruxtecan or trastuzumab emtansine, both...